ORLANDO, Fla.—Non-bone metastases are on the rise in men with metastatic castration-resistant prostate cancer (mCRPC), according to researchers.
Investigators led by William K. Oh, MD, of the Mount Sinai Icahn School of Medicine in New York, reviewed data from 127 studies of men with mCRPC that included reporting of non-osseous metastases and prior treatment. From 1990 to 2011, the rate of non-osseous metastasis increased significantly by 1.4% per year; the rate increased by 2.8% per year from 2000 to 2011. The rate for lymph node metastasis increased significantly by 2.2% per year from 1990 to 2011 and by 3.3% from 2000 to 2011, Dr. Oh’s group reported at the annual Genitourinary Cancers Symposium. The annual rate for liver metastasis remained stable during these study periods.
“It is possible that new treatments, including bone-targeted agents such as denosumab and zoledronic acid, are increasing non-bone metastases,” said Dr. Oh, Chief of the Division of Hematology and Medical Oncology and Associate Director of Mount Sinai’s Tisch Cancer Institute. In addition, Dr. Oh observed that men with mCRPC are probably living longer, which is likely to affect their sites of metastases.